The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 04, 2023

Filed:

Oct. 05, 2018
Applicant:

Sanofi Pasteur, Lyons, FR;

Inventors:

Diana Coronel, Mexico City, MX;

Betzana Zambrano, Montevideo, UY;

Fernando Noriega, Cresco, PA (US);

Tram Anh Wartel, Singapore, SG;

Yves Girerd-Chambaz, Paris, FR;

Assignee:

SANOFI PASTEUR, Lyons, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); A61P 31/14 (2018.01); A61K 2039/545 (2013.01); A61K 2039/70 (2013.01);
Abstract

The present invention is directed to a method of booster vaccination and to a vaccine composition for use in such a method, for inducing in a human subject a neutralizing antibody response, wherein said subject has previously received a primary vaccination against each of serotypes 1 to 4 of dengue virus and was dengue naïve before said primary vaccination, said composition comprising a dengue antigen of at least one of serotypes 1 to 4 or a nucleic acid construct capable of expressing said antigens in the subject, wherein said booster vaccination results in a 2-fold increase in the neutralizing antibody titre against each of serotypes 1 to 4. The invention is also directed to a method of inducing in a human subject a neutralizing antibody response comprising the administration of a vaccine composition, or to a vaccine composition for use in such a method, said composition comprising a dengue antigen of each of serotypes 1 to 4, or a nucleic acid construct capable of expressing in said subject a dengue antigen of each of serotypes 1 to 4; wherein said composition is administered as a primary vaccination, followed by a booster vaccination, and wherein the human subject is initially dengue naïve.


Find Patent Forward Citations

Loading…